Symptom-based NOWS dosing shortened readiness; hospital stay remained uncertain

In the 23-hospital OPTimize NOW cluster-crossover trial, symptom-based opioid dosing shortened adjusted time to medical readiness by 2.3 days among 383 infants managed with Eat, Sleep, Console, while actual length of stay and treatment initiation were not significantly different.

OPTimize NOW tested a genuinely different pharmacologic strategy for neonatal opioid withdrawal syndrome (NOWS): give an opioid only when the site's withdrawal threshold is met, then escalate to a scheduled taper only after prespecified repeat-dose triggers. In the prespecified Eat, Sleep, Console (ESC) cohort, this shortened medical readiness for discharge by an adjusted 2.3 days. It did not produce a statistically significant reduction in actual hospital stay.

The clearest signal is about readiness, not discharge—and symptom-based dosing still became scheduled therapy for more than one in three treated infants.

What OPTimize NOW tested

This was an open-label, stratified cluster-crossover randomized trial at 23 US hospitals from March 25, 2024, to April 9, 2025, with the last 3-month assessment on July 15, 2025. Hospitals—not individual infants—were randomized to the order of two five-month dosing periods, separated by run-in and washout periods. Of 626 enrolled infants, 383 formed the prespecified ESC primary cohort: 189 during symptom-based periods and 194 during scheduled-taper periods. Another 243 infants at Finnegan-based sites contributed planned secondary analyses.

Eligible infants were born at 36 weeks' gestation or later, had documented second- or third-trimester opioid exposure, were assessed for withdrawal at a study site, and had at least one marker of being at risk for pharmacologic treatment. The trial excluded important groups including infants with major birth defects, neonatal encephalopathy, prior postnatal opioid exposure unrelated to NOWS treatment, respiratory support at 48 hours, or treatment already started at a referring hospital.